# Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources

> **NCT05196581** · PHASE2 · COMPLETED · sponsor: **Suzana Erico Tanni Minamoto** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Dispersible NaCl powder 10 sessions
- **DRUG:** Dispersible NaCl powder 5 sessions

## Key facts

- **NCT ID:** NCT05196581
- **Lead sponsor:** Suzana Erico Tanni Minamoto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196581, "Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05196581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*